

Provincial Dyspepsia Primary Care Pathway




Quick links:

[Pathway primer](#)

[Expanded details](#)

[Advice options](#)

[Patient pathway](#)



This primary care pathway was co-developed by primary and specialty care and includes input from multidisciplinary teams. It is intended to be used in conjunction with specialty advice services, when required, to support care within the medical home. Wide adoption of primary care pathways can facilitate timely, evidence-based support to physicians and their teams who care for patients with common low-risk GI conditions and improve appropriate access to specialty care, when needed. To learn more about primary care pathways, check out this [short video](#).

DYSPEPSIA PATHWAY PRIMER

- Although the causes of dyspepsia include esophagitis, peptic ulcer disease, *Helicobacter pylori* (*H. pylori*) infection, celiac disease, and rarely neoplasia, most patients with dyspepsia have **no organic disease with a normal battery of investigations, including endoscopy**. Dyspeptic symptoms in the general population are common. Estimates are that as high as 30% of individuals experience dyspeptic symptoms, while few seek medical care.
- The mechanism of this symptom complex isn't completely understood, but likely involves a combination of visceral hypersensitivity, alterations in gastric accommodation and emptying, and altered central pain processing.
- Differential diagnosis
 - There is frequent overlap between dyspepsia and gastroesophageal reflux disease (GERD). If the patient has predominant heartburn symptoms, refer to the [GERD pathway](#).
 - Dyspepsia also overlaps with irritable bowel syndrome (IBS), especially if upper abdominal bloating is a dominant symptom. In IBS, the predominant symptom complex includes bloating and relief after defecation.
 - Biliary tract pain should also be considered, with classic presentation being a post-prandial deep-seated crescendo-decrescendo right upper quadrant pain (particularly after a fatty meal) that builds over several hours and then dissipates. Often, it radiates to the right side towards the right scapula and may be associated with nausea and vomiting.
- To learn more about deprescribing PPIs, refer to the six vignettes in the [Provider Resources](#) section.

Checklist to guide in-clinic review of your patient with Dyspepsia	
<input type="checkbox"/>	Diagnostic criteria – Predominant symptoms (> 1 month): <ul style="list-style-type: none"> • Epigastric discomfort/pain • Upper abdominal bloating
<input type="checkbox"/>	Confirm absence of alarm features (see algorithm Box 3). If alarm features identified, refer for specialist consultation.
<input type="checkbox"/>	Identification and adjustment of medication and lifestyle factors that may cause/contribute to dyspepsia
<input type="checkbox"/>	Complete baseline investigations confirming no underlying medical condition causing dyspepsia (see algorithm Box 5).
<input type="checkbox"/>	Confirm negative <i>H. pylori</i> testing. If positive, refer to the H. pylori pathway .
<input type="checkbox"/>	If unsatisfactory response to management and / or inclusion of pharmacological therapy (see algorithm Box 7), consider using an advice service before referring. Otherwise, continue care in the Patient Medical Home.

EXPANDED DETAILS

1. Suspected dyspepsia

- Dyspepsia is characterized by epigastric pain or upper abdominal discomfort. It may be accompanied by a sense of abdominal distension or “bloating,” early satiety, belching, nausea, and/or loss of appetite.



- The Rome IV committee on functional GI disorders defines dyspepsia as one or more of the following symptoms for three months prior, with symptom onset \geq six months prior:
 - Postprandial fullness
 - Epigastric pain
 - Epigastric burning
 - Early satiety

2. Is it GERD?

- If the patient's predominant symptom is heartburn \pm regurgitation, refer to the [GERD pathway](#).

3. Alarm features

If any of the following alarm features are identified, refer for consultation/endoscopy. Include all identified alarm features in the referral to ensure appropriate triage.

- Family history (first-degree relative) of esophageal or gastric cancer
- Personal history of peptic ulcer disease
- Age $>$ 60 with new and persistent symptoms ($>$ 3 months)¹
- Unintended weight loss ($>$ 5% over 6-12 months)
- Progressive dysphagia
- Persistent vomiting (not associated with cannabis use)
- Black stool or blood in vomit (see [Primer on Black Stool](#) and [High Risk Rectal Bleeding Pathway](#))
- Iron deficiency anemia (see [Iron Primer](#) and [Iron Deficiency Anemia Pathway](#))
- **Note:** FIT testing is not required or suggested. It has only been validated for screening in asymptomatic individuals

Stronger consideration should be given for symptoms that are $>$ 3 months in duration and have failed a trial of PPI. Evidence suggests that alarm features poorly predict clinically significant pathology and should be factored into the entire patient presentation, not in isolation.

4. Medication and lifestyle review

- **Medication review**
 - Common culprits include ASA/NSAIDs/COX-2 inhibitors, corticosteroids, bisphosphonates, antibiotics, dabigatran, metformin, and iron or magnesium supplements.
 - Any new or recently prescribed or over the counter medications or herbal/natural products may be implicated, as virtually all medications can cause GI upset in some patients.
- **Lifestyle review**
 - Review and address lifestyle factors that may contribute to symptoms, including dietary triggers, alcohol use, weight management, caffeine intake, smoking and stress.
 - Encourage patients to use the [Gut Health Patient Journal](#) to track symptoms, diet, and lifestyle factors.
 - Consider the following dietary recommendations:
 - Eat small, frequent meals throughout the day
 - Eat meals slowly and avoid eating late at night
 - Limit high fat or highly processed foods
 - Engage other health professionals, as appropriate (nurse, dietitian, pharmacist, etc.).

¹ There is some variation between guidelines about the age at which dyspepsia symptoms are more concerning and warrant stronger consideration of gastroscopy. Choosing Wisely Canada now uses age 65. However, age is only one element of a risk assessment related to the need for gastroscopy to investigate dyspepsia symptoms.



- Heavy cannabis use can be associated with persistent vomiting/other GI symptoms and should be considered and addressed, if appropriate.

5. Baseline investigations

- Baseline investigations to identify concerning features or clear etiologies include CBC, ferritin, and TTG IGA.
- Upper GI series is not recommended for investigation of dyspepsia due to high rates of false positives and false negatives.
- If hepatobiliary or pancreatic disease is suspected, consider abdominal ultrasound, ALT, ALP, bilirubin, and lipase (lipase \geq 3 times upper normal limit may be indicative of acute pancreatic disease).
- Pancreatic cancer should be considered in patients with dyspepsia and weight loss, especially if there is evidence of jaundice. The investigation of choice for suspected pancreatic cancer is an **urgent CT scan**.

6. Test and treat for *H. pylori* Infection

- See [H. pylori pathway](#)

7. Pharmacological therapy

Treatment options (pharmacological)	
Proton pump inhibitors (PPIs)	<ul style="list-style-type: none"> • Evidence: In the absence of <i>H. pylori</i> infection, or if symptoms continue despite <i>H. pylori</i> eradication, a trial of PPI may benefit some patients. • Mechanism of action: Suppresses gastric acid secretion by inhibiting the parietal cell H⁺/K⁺ ATP pump. • Initial PPI therapy should be once daily, 30 minutes before breakfast on an empty stomach. • If there is inadequate response after 4-8 weeks, step up to BID dosing for another 4-8 weeks. • If symptoms are controlled, it is advisable for most patients to titrate the PPI down to the lowest effective dose and attempt once yearly to taper or stop PPI use. • PPI deprescribing resources are available on the Digestive Health Strategic Clinical Network website • At standard doses, there are no major differences in efficacy between PPIs. • Commonly prescribed agents: <ul style="list-style-type: none"> ○ Rabeprazole - 20 mg ○ Pantoprazole - 40 mg ○ Dexlansoprazole - 30 mg ○ Omeprazole - 20 mg ○ Lansoprazole - 30 mg ○ Esomeprazole - 40 mg • See Table 1 for PPI pricing.
Optional or while awaiting specialist consultation	
Tricyclic antidepressants (TCAs)	<ul style="list-style-type: none"> • Evidence: Shown to reduce dyspepsia symptoms in RCTs for IBS.² • Mechanism of action: Involvement of the gut–brain axis and abnormal central pain processing in functional gastrointestinal disorders is now established, and central neuromodulators, including low-dose antidepressants, have been suggested as a therapy for many years because of their peripheral pain modifying effects.³ • Place in therapy: If patient has no response to PPI therapy, the Canadian Association of Gastroenterology guidelines suggest a trial of a TCA prior to a prokinetic based on superior evidence available.² • Adverse effects: Anticholinergic and antihistaminic (drowsiness/insomnia, xerostomia, palpitations, weight gain, constipation, urinary retention).⁴

² Canadian Association of Gastroenterology. (2017). ACG and CAG Clinical Guideline: Management of Dyspepsia. Retrieved from: https://www.cag-acg.org/images/publications/CAG_CPG_Dyspepsia_AJG_Aug2017.pdf

³ Ford, A. C., Mahadeva, S., Carbone, F., Lacy, B. E., & Talley, N. J. (2020). Functional dyspepsia. *The Lancet*, 396(10263). [https://doi.org/10.1016/S0140-6736\(20\)30469-4](https://doi.org/10.1016/S0140-6736(20)30469-4).

⁴ Lexicomp, Inc., Lexi-Drugs Online, Hudson, Ohio: UpToDate, Inc; 2013; [cited 27 Apr 2021].



	<ul style="list-style-type: none"> • Use with caution in patients at risk of prolonged QT. • It can take 2-3 months to reach maximum effect. • The lowest effective dose should be used. • Dose should be gradually reduced if discontinuing.
Tricyclic antidepressants (TCAs) cont'd	<p>Recommended Medications⁵</p> <ul style="list-style-type: none"> • Nortriptyline- 10-25 mg qhs. Increase dose by 10-25 mg every 3-4 weeks based on response and tolerability. May require up to 50 mg/day. Often takes 2-3 months for peak effect. (\$20-60/month). • Amitriptyline - 10-25 mg qhs. Increase dose by 10-25 mg every 3-4 weeks based on response and tolerability. May require up to 50 mg/day. Often takes 2-3 months for peak effect. (\$15-20/month). • Desipramine - 25 mg qhs. Increase based on response and tolerability (~\$25/month).
Domperidone	<ul style="list-style-type: none"> • Evidence: Prokinetic agents may reduce dyspepsia symptoms for some patients, however there is minimal evidence to support use as a first line agent.² • Mechanism of action: A prokinetic agent increases esophageal peristalsis, increases lower esophageal sphincter pressure, increases gastric motility and peristalsis, thus facilitating gastric emptying.² • Place in therapy: For patients < 60 who have failed PPI and TCA, a prokinetic agent may be offered.² • Prior to initiation, ensure patient has: <ul style="list-style-type: none"> ○ Normal QT interval (baseline ECG recommended) ○ No family history of sudden cardiac death ○ No personal history of underlying cardiac history (i.e., heart failure) ○ No current medications that increase the QT interval • Withhold treatment if: <ul style="list-style-type: none"> ○ QTc is > 470 ms in males ○ QTc is > 450 ms in females • Starting dose is 5 mg TID AC, titrating up to 10 mg TID AC as a 2–4-week trial.

- Domperidone and/or TCA trials are appropriate within primary care, but not required prior to making a referral. If deemed clinically appropriate, these trials could occur while awaiting specialist consultation.
- There is insufficient data to recommend the routine use of bismuth, antacids, simethicone, misoprostol, anti-cholinergics, anti-spasmodics, SSRIs, herbal therapies, probiotics, or psychological therapies in dyspepsia. However, these therapies may benefit some patients and, thus, a trial with assessment of response may be reasonable, if clinically appropriate, and could be undertaken while awaiting specialist consultation.

Table 1 – PPI Pricing

PPI	Strength	Estimated 90-day cost (2023) ⁶	Coverage
Rabeprazole	20 mg	\$25	Covered by Blue Cross/non-insured health benefits
Pantoprazole	40 mg	\$35	Covered by Blue Cross/non-insured health benefits
Omeprazole	20 mg	\$35	Covered by Blue Cross/non-insured health benefits
Lansoprazole	30 mg	\$65	Covered by Blue Cross/non-insured health benefits
Esomeprazole	40 mg	\$210	Not covered by Blue Cross/non-insured health benefits

⁵ Black CJ, Paine PA, Agrawal A, et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut 2022;71:1697-1723. <https://doi.org/10.1136/gutjnl-2022-327737>

⁶ Maximum Allowable Cost (MAC) pricing exists for PPIs paid for by Alberta government sponsored drug programs. See [link](#) for details.



Dexlansoprazole	30 mg	\$265	Not covered by Blue Cross/non-insured health benefits
-----------------	-------	-------	---

8. When to refer for consultation and/or endoscopy

- If alarm features are identified
- If unsatisfactory response to management and/or pharmacological therapy
 - **Note:** Consider using an advice service before referring
- Provide as much information as possible on the referral form, including identified alarm feature(s), important findings, and treatment/management strategies trialed with the patient.

Still concerned about your patient?

The primary care physician is typically the provider who is most familiar with their patient's overall health and knows how they tend to present. Changes in normal patterns, or onset of new or worrisome symptoms, may raise suspicion for a potentially serious diagnosis, even when investigations are normal and typical alarm features are not present.

There is evidence to support the importance of the family physician's intuition or "gut feeling" about patient symptoms, especially when the family physician is worried about a sinister cause such as cancer. A meta-analysis examining the predictive value of gut feelings showed that the odds of a patient being diagnosed with cancer, if a GP recorded a gut feeling, were 4.24 times higher than when no gut feeling was recorded.⁷

When a "gut feeling" persists despite normal investigations, and you decide to refer your patient for specialist consultation, document your concerns on the referral with as much detail as possible. Another option is to seek specialist advice (see [Advice Options](#)) to convey your concerns.

PRIMERS

Primer on Black Stool

- Possible causes of black stool
 - Upper GI bleeding
 - Slow right-sided colonic bleeding
 - Epistaxis or hemoptysis with swallowed blood
- Melena is dark/black, sticky, tarry, and has a distinct odour
- Patient history should include:
 - Any prior GI bleeds or ulcer disease
 - Taking ASA, NSAIDs, anticoagulants, antiplatelets, Pepto Bismol®, SSRIs, or iron supplements
 - Significant consumption of black licorice
 - Significant alcohol history or hepatitis risk factors
 - Any other signs of bleeding (e.g., coffee ground emesis, hematemesis, hematochezia, or bright red blood per rectum)
 - Any dysphagia, abdominal pain, change in bowel movements, constitutional symptoms, or signs/symptoms of significant blood loss
- Physical exam should include vitals (including postural if worried about GI bleeding) and a digital rectal exam for direct visualization of the stool to confirm, in addition to the remainder of the exam.
- Initial labs to consider include CBC, BUN (may be elevated with upper GI bleeding), INR.

⁷ Friedemann Smith, C., Drew, S., Ziebland, S., & Nicholson, B. D. (2020). Understanding the role of General Practitioners' gut feelings in diagnosing cancer in primary care: A systematic review and meta-analysis of existing evidence. *British Journal of General Practice*, 70(698), e612-e621.



- If the patient is actively bleeding, suggest calling GI on call and/or the ED for assessment, possible resuscitation, and possible endoscopic procedure.

Iron Primer

Evaluation of measures of iron storage can be challenging. Gastrointestinal (occult) blood loss is a common cause of iron deficiency and should be considered as a cause when iron deficiency anemia is present. Menstrual losses should also be considered.

There are two serological tests to best evaluate iron stores (ferritin, transferrin saturation) - neither of which are perfect.

The first step is to evaluate **ferritin**:

- If the ferritin is below the lower limit of normal (lower limit of normal is 30 µg/L for men and 20 µg/L for women), it is diagnostic of iron deficiency with high specificity (98% specificity).
- Ferritin is an acute phase reactant which may be elevated in the context of acute inflammation and infection. If ferritin is normal or increased, and you suspect it may be acting as an acute phase reactant, order a transferrin saturation test (see below).
 - However, if the ferritin is > 100 µg/L and there is no concurrent significant chronic renal insufficiency, iron deficiency is very unlikely - even in the context of acute inflammation/infection.

The second step is to evaluate **transferrin saturation**:

- The transferrin saturation is a calculated ratio using serum iron and total iron binding capacity. Serum iron alone does **not** reflect iron stores.
- Low values (< 16%) demonstrate low iron stores in conjunction with a ferritin < 100 µg/L.

In the absence of abnormal iron indices, anemia may be from other causes other than GI (occult) blood loss (e.g., bone marrow sources, thalassemia, and sickle cell anemia).

BACKGROUND

About this Pathway

- Digestive health primary care pathways were originally developed in 2015 as part of the Calgary Zone's Specialist LINK initiative. They were co-developed by the Department of Gastroenterology and the Calgary Zone's specialty integration group, which includes medical leadership and staff from Calgary and area Primary Care Networks, the Department of Family Medicine, and Alberta Health Services.
- The pathways were intended to provide evidence-based guidance to support primary care providers in caring for patients with common digestive health conditions within the medical home.
- Based on the successful adoption of the primary care pathways within the Calgary Zone, and their impact on timely access to quality care, in 2017 the Digestive Health Strategic Clinical Network (DHSCN) led an initiative to validate the applicability of the pathways for Alberta and to spread availability and foster adoption of the pathways across the province.

Authors & Conflict of Interest Declaration

This pathway was reviewed and revised under the auspices of the DHSCN in 2024, by a multi-disciplinary team led by family physicians and gastroenterologists. For more information, contact the DHSCN at Digestivehealth.SCN@ahs.ca.

Pathway Feedback and Review Process

Primary care pathways undergo scheduled review every three years, or earlier if there is a clinically significant change in knowledge or practice. The next scheduled review is Spring 2027; however, we welcome feedback at any time.



Copyright Information



This work is licensed under a [Creative Commons Attribution-Non-commercial-Share Alike 4.0 International](https://creativecommons.org/licenses/by-nc-sa/4.0/) license. You are free to copy, distribute, and adapt the work for non-commercial purposes, as long as you attribute the work to Alberta Health Services and Primary Care Networks and abide by the other license terms. If you alter, transform, or build upon this work, you may distribute the resulting work only under the same, similar, or compatible license. The license does not apply to content for which the Alberta Health Services is not the copyright owner.

Disclaimer

This pathway represents evidence-based best practice but does not override the individual responsibility of health care professionals to make decisions appropriate to their patients using their own clinical judgment given their patients' specific clinical conditions, in consultation with patients/alternate decision makers. The pathway is not a substitute for clinical judgment or advice of a qualified health care professional. It is expected that all users will seek advice of other appropriately qualified and regulated health care providers with any issues transcending their specific knowledge, scope of regulated practice or professional competence.

PROVIDER RESOURCES

Advice Options

Non-urgent advice is available to support family physicians.

- Gastroenterology advice is available across the province via Alberta Netcare eReferral Advice Request (responses are received within five calendar days). View the [Referring Provider – FAQ](#) document for more information.
- Non-urgent telephone advice connects family physicians and specialists in real time via a tele-advice line. Family physicians can request non-urgent advice from a gastroenterologist:
 - In the Calgary Zone at specialistlink.ca or by calling 403-910-2551. This service is available from 8:00 a.m. to 5:00 p.m. Monday to Friday (excluding statutory holidays). Calls are returned within one (1) hour.
 - In the Edmonton and North Zones by calling 1-844-633-2263 or visiting pcnconnectmd.com. This service is available from 9:00 a.m. to 6:00 p.m. Monday to Thursday and from 9:00 a.m. to 4:00 p.m. Friday (excluding statutory holidays and Christmas break). Calls are returned within two (2) business days.

Nutrition Services

To refer your patient to a Registered Dietitian:

- Visit [Alberta Referral Directory](#) and search for nutrition counselling.
- To learn more about programs and services offered in your zone, visit ahs.ca/Nutrition.
- Health Link has Registered Dietitians available to answer nutrition questions. If a patient has a nutrition question, they can complete a self-referral at ahs.ca/811 or call 811 and ask to talk to a dietitian.

Resources	
Poverty: A Clinical Tool for Primary Care Providers (AB)	cep.health/media/uploaded/Poverty_flowAB-2016-Oct-28.pdf
Food Insecurity Nutrition Guideline	https://www.albertahealthservices.ca/nutrition/Page18033.aspx
PPI Deprescribing Vignettes	<ul style="list-style-type: none">• Predicting Dyspepsia Patient Resources to PPI - youtu.be/XT0MxefpNYQ• Clinical Diagnosis of GERD - youtu.be/d_M8_S8lcyI• How to Know if PPI is working - youtu.be/tttOBXPLR7U



	<ul style="list-style-type: none"> • GERD Patients and PPI Doses - youtu.be/u15sPirE4EE • How is Dyspepsia Defined? - youtu.be/F0E5rce-NSM • Addressing Return of Symptoms - youtu.be/9008u9kyyDU
--	---

PATIENT RESOURCES

Description	Website
General information on dyspepsia (MyHealth.Alberta.ca)	myhealth.alberta.ca/health/pages/conditions.aspx?Hwid=tm6322
Information on domperidone (MyHealth.Alberta.ca)	myhealth.alberta.ca/Health/medications/Pages/conditions.aspx?hwid=fdb6090
Gut Health Patient Journal (Physician Learning Program)	9c849905-3a37-465a-9612-7db1b9a0a69c.filesusr.com/ugd/7b74c1_81f1695f08214a66bc339462c52cd0111.pdf
Dyspepsia Resources (Physician Learning Program)	albertapl.ca/our-tools
General information on weight management (MyHealth.Alberta.ca)	myhealth.alberta.ca/health/healthy-living/pages/conditions.aspx?Hwid=center1038
Online learning module on weight management (MyHealth.Alberta.ca)	myhealth.alberta.ca/learning/modules/Weight-Management
Nutrition Education Material	ahs.ca/NutritionResources
Nutrition Workshops & Classes	ahs.ca/NutritionWorkshops
Supports for working towards healthy lifestyle goals and weight management (Weight Management – AHS)	ahs.ca/info/Page15163.aspx
Supports to quit smoking (Alberta Quits)	albertaquits.ca
Ask a Dietician a Nutrition Question	Complete a self-referral at ahs.ca/811 or call 811 and ask to talk to a dietician

PATIENT PATHWAY

- [Dyspepsia patient pathway](#)



References

Amerikanou, C., Kleftaki, S-A., Valsamidou, E., Chroni, E., Biagki, T., Sigala, D., Koutoulogenis, K., Anapliotis, P., Gioxari, A., Kaliora, AC. (2023). Food, Dietary Patterns, or Is Eating Behavior to Blame? Analyzing the Nutritional Aspects of Functional Dyspepsia. *Nutrients*, 15(6):1544. <https://doi.org/10.3390/nu15061544>

Ansari, S., & Ford, A. C. (2013). Initial management of dyspepsia in primary care: an evidence-based approach. *British Journal of General Practice*, 63(614), 498-499. bjgp.org/content/63/614/498

Black CJ, Paine PA, Agrawal A, et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. *Gut* 2022;71:1697-1723. <https://doi.org/10.1136/gutjnl-2022-327737>

Farrell, B., Pottie, K., Thompson, W., Boghossian, T., Pizzola, L., Rashid, F. J., ... & Moayyedi, P. (2017). Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. *Canadian Family Physician*, 63(5), 354-364. cfp.ca/content/63/5/354

Ford, A. C., Mahadeva, S., Carbone, F., Lacy, B. E., & Talley, N. J. (2020). Functional dyspepsia. *The Lancet*, 396(10263). [https://doi.org/10.1016/S0140-6736\(20\)30469-4](https://doi.org/10.1016/S0140-6736(20)30469-4).

Ikenberry, S. O., Harrison, M. E., Lichtenstein, D., Dominitz, J. A., Anderson, M. A., Jagannath, S. B., ... & Shen, B. (2007). The role of endoscopy in dyspepsia. *Gastrointestinal endoscopy*, 66(6), 1071-1075. asge.org/docs/default-source/education/practice_guidelines/doc-dyspepsia_aip.pdf?sfvrsn=6

Moayyedi, P. M., Lacy, B. E., Andrews, C. N., Enns, R. A., Howden, C. W., & Vakil, N. (2017). ACG and CAG clinical guideline: management of dyspepsia. *American Journal of Gastroenterology*, 112(7), 988-1013. acg.org/images/publications/CAG_CPG_Dyspepsia_AJG_Aug2017.pdf

Nasseri-Moghaddam, S., Mousavian, A. H., Kasaeian, A., Kanno, T., Yuan, Y., Ford, A. C., & Moayyedi, P. (2023). What is the Prevalence of Clinically Significant Endoscopic Findings in Subjects With Dyspepsia? Updated Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, 21(7), 1739-1749e2. <https://doi.org/10.1016/j.cgh.2022.05.041>

Dyspepsia resources from the Physician Learning Program for promoting patient education and self-management. albertaplp.ca/our-tools

- Poster #1 - albertaplp.ca/our-tools?lightbox=dataltm-knr1hq2h1
- Poster #2 - albertaplp.ca/our-tools?lightbox=dataltm-knr1hq2n2
- Gut Health Patient Journal - 9c849905-3a37-465a-9612-7db1b9a0a69c.filesusr.com/ugd/7b74c1_81f1695f08214a66bc339462c52cd011.pdf

Resources for appropriate PPI prescribing. Alberta Health Services – Digestive Health Strategic Clinical Network website.

- PPI guideline - ahs.ca/assets/about/scn/ahs-scn-dh-ppi-guideline.pdf
- PPI co-decision making tool - ahs.ca/assets/about/scn/ahs-scn-dh-ppi-decision-tool.pdf
- PPI patient poster - ahs.ca/assets/about/scn/ahs-scn-dh-ppi-patient-poster.pdf

van Zanten, S. J. V., Flook, N., Chiba, N., Armstrong, D., Barkun, A., Bradette, M., ... & Sinclair, P. (2000). An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. *Canadian Medical Association Journal*, 162(12 suppl), S3-S23. cmaj.ca/content/162/12_suppl/S3

